Article
Medicine, Research & Experimental
Federica Campolo, Franz Sesti, Tiziana Feola, Giulia Puliani, Antongiulio Faggiano, Maria Grazia Tarsitano, Marta Tenuta, Valeria Hasenmajer, Elisabetta Ferretti, Monica Verrico, Daniele Gianfrilli, Mary Anna Venneri, Andrea M. M. Isidori, Elisa Giannetta
Summary: This proof-of-concept study demonstrates that circRNA signatures from tumor-educated platelets may serve as liquid biopsy biomarkers for the detection of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and the prediction of early treatment response.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Genetics & Heredity
Midie Xu, Jiuliang Yan, Beiyuan Hu, Chuntao Wu, Haitao Gu, Zihao Qi, Tao Chen, Wenting Yang, Yan Zheng, Hanguang Dong, Weiqi Sheng, Jiang Long
Summary: This study analyzed the genomic variations between primary and metastatic tumors in PanNETs patients, finding low genomic heterogeneity and evidence of polyclonal seeding during metastatic progression. Copy number variations of BRCA1/BRCA2 were associated with better prognosis. Pathways in cancer, DNA repair, and cell cycle regulation were significantly enriched. The study provides novel insight into genetic changes in metastatic tumors of PanNETs.
Review
Medicine, General & Internal
Busra Aydin, Aysegul Caliskan, Kazim Yalcin Arga
Summary: Pituitary neuroendocrine tumors (PitNETs) are the second most common type of intracranial neoplasia, requiring effective management due to hormone hypersecretion. Diagnosis of non-functioning PitNETs can be challenging, with some tumors showing resistance or aggressive behavior. Early detection or identification of recurrence and remission post-surgery for hormone-secreting tumors is crucial for wiser disease management.
Article
Endocrinology & Metabolism
Jiangping Wu, Jing Guo, Qiuyue Fang, Yulou Liu, Chuzhong Li, Weiyan Xie, Yazhuo Zhang
Summary: This study identified eight key genes associated with invasion and immunity in NF-PitNEts, which may play a fundamental role in invasive progression and could potentially serve as novel immunotherapy targets for NF-PitNEts.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Multidisciplinary Sciences
Nishte Rassol, Charlotte Andersson, Daniella Pettersson, Amin Al-Awar, Emman Shubbar, Aniko Kovacs, Bo Akerstrom, Magnus Gram, Khalil Helou, Eva Forssell-Aronsson
Summary: The aim of this study was to investigate the regulation of apoptosis-related genes in GOT1 tumors after administration of Lu-177-octreotate with or without A1M. The results showed that co-administration of A1M did not negatively affect the apoptotic response of Lu-177-octreotate in GOT1 tumors.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Andrea Necchi, Vito Cucchiara, Petros Grivas, Gennady Bratslavsky, Joseph Jacob, Philippe E. Spiess, Ethan S. Sokol, Jonathan Keith Killian, Douglas Lin, Shakti Ramkissoon, Richard S. P. Huang, Russell W. Madison, Jeffrey M. Venstrom, Alexa B. Schrock, Natalie Danziger, Brennan Decker, Ole Gjoerup, Ryon P. Graf, Geoffrey R. Oxnard, Hanna Tukachinsky, Jeffrey S. Ross
Summary: This study assessed the genomic profiles of primary tumors, metastatic sites, and circulating tumor DNA in prostate cancer patients, revealing differences in alteration frequencies that are likely associated with tumor progression, clonal evolution, and exposure to therapies.
Article
Oncology
Beatriz Soldevilla, Angeles Lopez-Lopez, Alberto Lens-Pardo, Carlos Carretero-Puche, Angeles Lopez-Gonzalvez, Anna La Salvia, Beatriz Gil-Calderon, Maria C. Riesco-Martinez, Paula Espinosa-Olarte, Jacinto Sarmentero, Beatriz Rubio-Cuesta, Raul Rincon, Coral Barbas, Rocio Garcia-Carbonero
Summary: Metabolic flexibility is a key feature of cancer, and this study provides a comprehensive analysis of the metabolic profile of NET patients, identifying a unique metabolic signature in plasma with potential clinical applications. The study also identifies a reduced set of metabolites with high diagnostic accuracy and reveals 32 enriched metabolic pathways related to TCA cycle and amino acid metabolism in NETs.
Article
Surgery
Anna Malczewska, Adam E. Frampton, Mireia Mato Prado, Shima Ameri, Aleksandra F. Dabrowska, Sladjana Zagorac, Ashley K. Clift, Beata Kos-Kudla, Omar Faiz, Justin Stebbing, Leandro Castellano, Andrea Frilling
Summary: This study identified four serum miRNAs that were significantly up-regulated in SBNET, with miR-125b-5p and miR-362-5p showing potential to detect residual and recurrent disease. The longitudinal assessment revealed changes in miRNA expression after surgical resection, providing insights into disease progression and monitoring.
Review
Oncology
Jianming Xu
Summary: Neuroendocrine tumors are rare, heterogeneous tumors that often originate in the lungs and gastrointestinal tract. Surufatinib, a new small-molecule tyrosine kinase inhibitor, has shown promising efficacy in inhibiting tumor angiogenesis and overcoming tumor resistance in clinical studies conducted in China and the United States. The positive results from phase III trials support the use of surufatinib in treating advanced, progressive, well-differentiated NETs regardless of tumor origin.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Wenying Peng, Liming Cao, Likun Chen, Gen Lin, Bo Zhu, Xiaohua Hu, Yingcheng Lin, Sheng Zhang, Meilin Jiang, Jingyi Wang, Junjun Li, Chao Li, Lin Shao, Haiwei Du, Ting Hou, Zhiqiu Chen, Jianxing Xiang, Xingxiang Pu, Jia Li, Fang Xu, Herbert Loong, Lin Wu
Summary: We conducted a comprehensive genomic investigation on 4 pNET subtypes in the Chinese population, revealing distinctive genomic signatures in subtypes and providing new insights into the prognostic and therapeutic stratification of pNETs.
Article
Oncology
Enrique Grande, Cristina Rodriguez-Antona, Carlos Lopez, Teresa Alonso-Gordoa, Marta Benavent, Jaume Capdevila, Alex Teule, Ana Custodio, Isabel Sevilla, Jorge Hernando, Pablo Gajate, Javier Molina-Cerrillo, Juan Jose Diez, Maria Santos, Javier Lanillos, Rocio Garcia-Carbonero
Summary: The combination of Sunitinib and Evofosfamide showed moderate efficacy in pancreatic neuroendocrine tumors, with a median objective response rate of 17.6% and median progression-free survival of 10.4 months. However, treatment response did not correlate with analyzed biomarkers. The high systemic toxicity makes this therapeutic approach unfeasible and highlights the need for further research to overcome resistance to antiangiogenic agents in panNETs.
Article
Oncology
Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Lea Payen, Younes Mahi, Berengere Vire, Madison Sands, B. Mark Evers, Dominique Joubert, Lowell Anthony
Summary: Current blood-based biomarkers for neuroendocrine neoplasms lack sensitivity and specificity. This study examined the potential of human circulating progastrin as a biomarker for neuroendocrine neoplasms. The results showed that levels of circulating progastrin were significantly higher in neuroendocrine neoplasms patients and demonstrated high sensitivity and specificity. Plasma circulating progastrin may be a diagnostic blood biomarker for both low- and high-grade neuroendocrine neoplasms, but further research is needed.
Review
Biochemistry & Molecular Biology
Andrei Havasi, Daniel Sur, Simona Sorana Cainap, Cristian-Virgil Lungulescu, Laura-Ioana Gavrilas, Calin Cainap, Catalin Vlad, Ovidiu Balacescu
Summary: Pancreatic neuroendocrine tumors (PanNETs) are rare tumors that occur more frequently among the elderly. Despite their low incidence, they represent 5% of all pancreatic tumors and have poor prognosis in advanced stages and undifferentiated tumors. Functional PanNETs impact quality of life due to abnormal hormonal secretion. Limited therapeutic and diagnostic options emphasize the need for patient stratification and optimal therapeutic strategies. MicroRNAs (miRNAs) have shown potential as prognostic, predictive, or diagnostic biomarkers and therapeutic targets. This review discusses current and new challenges in PanNETs management, including genetic and epigenetic approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Giuseppe Lamberti, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Dario de Biase, Deborah Malvi, Mirta Mosca, Rossana Berardi, Toni Ibrahim, Sara Pusceddu, Davide Campana
Summary: This study investigated the molecular features and treatment response of grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET). The findings showed that FOLFOX/XELOX chemotherapy is effective as a first-line treatment for G3 GEP-NET. The mutational landscape of G3 NET is more similar to well-differentiated NETs.
Article
Cell Biology
Jiajia Li, Siqi Wen, Biao Li, Na Li, Xianquan Zhan
Summary: The study identified 595 differentially phosphorylated proteins in human nonfunctional pituitary neuroendocrine tumors (NF-PitNETs), with involvement in multiple biological processes and signaling pathways. Kinase analysis of these phosphorylated proteins revealed potential new drug targets. Further validation through experiments confirmed the research findings.
